October 25, 2018 | Chip Kahn
Category: Financing, Medicare, Pharmaceuticals
We agree with the President that it is time to reduce the drug tab for Americans, and actions need to be focused on the real culprit - manufacturers’ prices - not the frontline hospitals and physicians who administer and prescribe those medicines. We look forward to examining the details and fine print of the Administration’s proposals.
It is important that the plan aim at protecting patients and does not impede the freedom of physicians to prescribe the precise drug therapies their patients need.